First-line antiretroviral regimens prescribed in antiretroviral-naive individuals from the CoRIS cohort, 2018–2021. DTG + FTC/TDF, dolutegravir + emtricitabine/tenofovir disoproxil fumarate; EVG/COBI/FTC/TAF, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; DRV/COBI/FTC/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; DTG/3TC/ABC, dolutegravir/lamivudine/abacavir; BIC/FTC/TAF, bictegravir/emtricitabine/tenofovir alafenamide; DTG/3TC, dolutegravir/lamivudine.